Injectable Drugs for Diabetes Part 5 PDF

\#\#\# \*\*Slide 37: Continuous Glucose Monitoring (CGM)\*\* 1\. \*\*What is the purpose of continuous glucose monitoring (CGM) in diabetes management?\*\* \- A. To replace insulin therapy \- B. To provide real-time glucose levels and trends throughout the day \- C. To reduce the need for daily...

\#\#\# \*\*Slide 37: Continuous Glucose Monitoring (CGM)\*\* 1\. \*\*What is the purpose of continuous glucose monitoring (CGM) in diabetes management?\*\* \- A. To replace insulin therapy \- B. To provide real-time glucose levels and trends throughout the day \- C. To reduce the need for daily insulin injections \- D. To measure insulin resistance \*\*Answer:\*\* B. To provide real-time glucose levels and trends throughout the day 2\. \*\*Which parameter in CGM refers to the percentage of time that glucose levels are within the target range?\*\* \- A. Time above range (TAR) \- B. Time in range (TIR) \- C. Average daily glucose (ADG) \- D. Fasting blood glucose (FBG) \*\*Answer:\*\* B. Time in range (TIR) 3\. \*\*CGM is particularly beneficial for which patient group?\*\* \- A. Patients using multiple daily insulin injections \- B. Patients with prediabetes \- C. Patients with well-controlled type 2 diabetes on oral medications only \- D. Patients with no history of hypoglycemia \*\*Answer:\*\* A. Patients using multiple daily insulin injections \-\-- \#\#\# \*\*Slide 38: Monitoring Blood Glucose (Test Strips)\*\* 1\. \*\*What is an important consideration when ordering supplies for self-monitoring of blood glucose (SMBG)?\*\* \- A. Test strips should be compatible with the glucose meter \- B. Test strips should be used only once weekly \- C. Test strips are interchangeable between different devices \- D. Test strips should be shared among family members \*\*Answer:\*\* A. Test strips should be compatible with the glucose meter 2\. \*\*Why is it important to ensure patients have an adequate supply of test strips for SMBG?\*\* \- A. To reduce the risk of hyperglycemia \- B. To improve patient compliance and glycemic control \- C. To replace the need for insulin therapy \- D. To increase the effectiveness of oral diabetes medications \*\*Answer:\*\* B. To improve patient compliance and glycemic control 3\. \*\*Which of the following factors can affect the accuracy of blood glucose test strips?\*\* \- A. Storage temperature \- B. Frequency of use \- C. Type of insulin administered \- D. Time of day the test is performed \*\*Answer:\*\* A. Storage temperature \-\-- \#\#\# \*\*Slide 39: Hypoglycemia\*\* 1\. \*\*What is the first step in treating hypoglycemia in a diabetic patient?\*\* \- A. Administering glucagon immediately \- B. Identifying and addressing the underlying cause of hypoglycemia \- C. Increasing the insulin dose \- D. Withholding all diabetes medications \*\*Answer:\*\* B. Identifying and addressing the underlying cause of hypoglycemia 2\. \*\*Which of the following is a common cause of insulin-induced hypoglycemia?\*\* \- A. Overeating carbohydrates \- B. Skipping meals after insulin administration \- C. Performing regular exercise \- D. Taking oral diabetes medications \*\*Answer:\*\* B. Skipping meals after insulin administration 3\. \*\*In the absence of a clear cause of hypoglycemia, how should the insulin dose be adjusted?\*\* \- A. Reduce the dose by 4 units or 10-20% \- B. Increase the dose by 2 units \- C. Stop insulin therapy temporarily \- D. Switch to oral medications \*\*Answer:\*\* A. Reduce the dose by 4 units or 10-20% \-\-- \#\#\# \*\*Slide 40: Glucagon in Hypoglycemia\*\* 1\. \*\*What is the role of glucagon in the treatment of severe hypoglycemia?\*\* \- A. It stimulates the liver to release stored glucose \- B. It inhibits insulin secretion \- C. It reduces the rate of glucose absorption \- D. It increases insulin sensitivity \*\*Answer:\*\* A. It stimulates the liver to release stored glucose 2\. \*\*What is the typical onset time for glucagon\'s effect after administration?\*\* \- A. 1-2 hours \- B. 10-20 minutes \- C. 30-60 minutes \- D. 2-4 hours \*\*Answer:\*\* B. 10-20 minutes 3\. \*\*For a child under 6 years of age or weighing less than 25 kg, what is the recommended dose of glucagon for hypoglycemia?\*\* \- A. 1 mg \- B. 0.5 mg \- C. 2 mg \- D. 0.1 mg \*\*Answer:\*\* B. 0.5 mg \-\-- \#\#\# \*\*Slide 41: Glucagon Administration\*\* 1\. \*\*Glucagon can be administered via which of the following routes?\*\* \- A. Oral \- B. Intravenous (IV), intramuscular (IM), and subcutaneous (SC) \- C. Transdermal patch \- D. Inhalation \*\*Answer:\*\* B. Intravenous (IV), intramuscular (IM), and subcutaneous (SC) 2\. \*\*When is intranasal glucagon considered for use in patients with hypoglycemia?\*\* \- A. When IV access is unavailable \- B. As a routine replacement for SC glucagon \- C. Only in cases of hyperglycemia \- D. When oral glucose is not tolerated \*\*Answer:\*\* A. When IV access is unavailable 3\. \*\*If a patient does not respond to the initial dose of glucagon, when can the dose be repeated?\*\* \- A. 10 minutes later \- B. 15-20 minutes later \- C. 30 minutes later \- D. After 1 hour \*\*Answer:\*\* B. 15-20 minutes later \-\-- \#\#\# \*\*Slide 42: Incretins Overview\*\* 1\. \*\*What is the role of GLP-1 (glucagon-like peptide-1) in glucose metabolism?\*\* \- A. It stimulates insulin secretion and inhibits glucagon release \- B. It increases glucagon secretion and decreases insulin secretion \- C. It increases the absorption of glucose in the intestines \- D. It accelerates gastric emptying \*\*Answer:\*\* A. It stimulates insulin secretion and inhibits glucagon release 2\. \*\*Which enzyme breaks down GLP-1 in the body, reducing its activity?\*\* \- A. Amylase \- B. DPP-4 (dipeptidyl peptidase-4) \- C. GLP-2 \- D. Alpha-glucosidase \*\*Answer:\*\* B. DPP-4 (dipeptidyl peptidase-4) 3\. \*\*GLP-1 agonists are used in diabetes management to:\*\* \- A. Increase hepatic glucose production \- B. Decrease food intake and promote satiety \- C. Increase glucagon secretion \- D. Speed up the breakdown of insulin \*\*Answer:\*\* B. Decrease food intake and promote satiety \-\-- \#\#\# \*\*Slide 43: GLP-1 Agonists (Mechanism of Action)\*\* 1\. \*\*How do GLP-1 agonists help manage blood glucose levels in type 2 diabetes?\*\* \- A. They increase insulin secretion and decrease glucagon secretion \- B. They increase glucagon secretion and reduce insulin resistance \- C. They promote the breakdown of glycogen in the liver \- D. They reduce hepatic glucose production only \*\*Answer:\*\* A. They increase insulin secretion and decrease glucagon secretion 2\. \*\*Which of the following is a benefit of GLP-1 agonist therapy?\*\* \- A. Weight loss \- B. Weight gain \- C. Increased insulin resistance \- D. Increased triglyceride production \*\*Answer:\*\* A. Weight loss 3\. \*\*GLP-1 agonists help reduce hemoglobin A1C by approximately:\*\* \- A. 0.5% \- B. 1% \- C. 2% \- D. 3% \*\*Answer:\*\* B. 1%